Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|8|1016-1022

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.8, 2015-08, pp. : 1016-1022

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor‐β‐mediated growth inhibition in hepatocellular carcinoma

By  

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 929-937

John Wiley & Sons Inc

Access to resources Recommend Favorite

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancer

By  

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1722-1729

John Wiley & Sons Inc

Access to resources Recommend Favorite

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

By  

Cancer Science, Vol. 107, Iss. 9, 2016-09 ,pp. : 1179-1186

John Wiley & Sons Inc

Access to resources Recommend Favorite

MiR‐940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients

By  

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 819-824

John Wiley & Sons Inc

Access to resources Recommend Favorite

Emulsion electrospun vascular endothelial growth factor encapsulated poly(l-lactic acid-co-ε-caprolactone) nanofibers for sustained release in cardiac tissue engineering

By Tian Lingling   Prabhakaran Molamma   Ding Xin   Kai Dan   Ramakrishna Seeram  

Journal of Materials Science, Vol. 47, Iss. 7, 2012-04 ,pp. : 3272-3281

Springer Publishing Company

Access to resources Recommend Favorite